PRF’s 2019 Newsletter
Get exciting updates on our progress over the past year, learn why we now refer to the population we serve as children – and young adults – with Progeria, check…
Category: News
‘Find the Children’ campaign launches in India
Due to the incredible success of previous years’ campaigns in 2009 and 2015, we are thrilled to announce the 2019 launch our ‘Find the Children’ initiative to search globally for…
2019 International Race for Research – Photos & Race Times
PRF's 18th Annual International Race for Research is complete! Thank you to all who helped make it a success! Get your photos and official race times here.
ONEpossible 2019 a Success!!
THANK YOU to all of our donors who helped us meet our goal. You are all ONE to make the cure POSSIBLE!
![Ted Danson and Cast of The Good Place® Support PRF! [Ended July 1st]](https://www.progeriaresearch.org/wp-content/uploads/2019/05/TedHP.jpg)
Ted Danson and Cast of The Good Place® Support PRF! [Ended July 1st]
Care to join Ted on The Good Place set for lunch? You’ll even get a behind-the-scenes look at their next season and meet the rest of the cast! ENTER to…
Exciting Updates!
The Progeria Research Foundation has some exciting updates we would like to share!
Meghan’s March Madness!
Thank YOU for celebrating Meghan’s March Madness with us! Because of all of you we raised over $19,000, which will go directly to our mission to find the cure! We…
October 2018: PRF Redesigns the Research Grant Program and is Soliciting Grant Proposals Worldwide
Letters of Intent are due Oct. 30, 2018. For information on submitting an application and the complete PRF grant program, please visit the PRF Website here.
Our 2018 Newsletter is Here!
Read about our remarkable progress over the past year, the latest developments in our clinical trial, our wonderful Chapters and Volunteers and so much more.
On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib
On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib.
